Experimental dietary supplement encourages Mouse behavior related to Angelman Syndrome: Research Findings
In a groundbreaking study published in The FASEB Journal, researchers led by Dr. Daniela C. Zampieri have shown that dietary intake of octanoic acid (OA) could potentially be a non-invasive and safe therapy for Angelman syndrome.
The study revealed that OA, a naturally occurring fatty acid found in breast milk, can cross the blood-brain barrier, making it a suitable candidate for early treatment during pregnancy and gestation. This is particularly significant as it could prove more efficacious in reversing the phenotypic deficits observed in Angelman syndrome animals during critical periods of brain development.
In the study, OA was found to increase UBE3A protein levels in nerve cells derived from the mouse model of Angelman syndrome. This unsilencing of the paternal Ube3a gene in neuronal cultures could be a potential treatment strategy for the condition, as previous approaches have faced challenges with effects on other genes, invasive procedures, and precise dosing.
The importance of this finding lies in the fact that only the maternal copy of the UBE3A gene is active in nerve cells of the brain, while the paternal copy is inactive. When the maternal gene copy is mutated, symptoms of Angelman syndrome occur. By reactivating the silenced, paternal Ube3a allele, OA helped improve memory and cognition in the mice.
The improvements were particularly pronounced in the hippocampus, an area of the brain involved in learning and memory. Mice exposed to OA performed better on behavioral tests, showing better short-term spatial memory and building more normal nests.
However, more research is needed to examine effective OA doses. Stem cell-derived neurons from people with Angelman syndrome could be used as a model for further research. The study suggests that dietary supplementation with OA should be explored as a potential therapy for Angelman syndrome during prenatal and postnatal development and into adulthood.
The study, titled "Dietary Intake of Octanoic Acid Restores UBE3A Expression and Improves the Behavioral Phenotypes in a Mouse Model of Angelman Syndrome," offers a promising new avenue for the treatment of this debilitating condition. With further research, OA supplementation could potentially provide a safe and effective therapy for individuals with Angelman syndrome.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
